U.S. Heparin Market to Garner Significant Returns Through 2026

December 17, 2020


According a recent study titled U.S. Heparin Market Size By Product, By Application, By Distribution Channel, Application Potential, Price Trends, Competitive Market Share & Forecast, 2020 - 2026’, available with Market Study Report LLC, U.S. heparin market size is anticipated to expand considerably over 2020-2026.
 

As per the report findings, rising cases of chronic ailments like venous thromboembolism, and increasing genetic risk factors among the population are fueling U.S. heparin market growth. Moreover, booming geriatric population who are susceptible to various health conditions is adding considerable traction to the industry growth.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/3076883/
 

For those unfamiliar, Heparin is an essential anticoagulant mainly utilized to treat and prevent blood clots caused by certain medical procedures or health conditions. It keeps the blood flowing smoothly into the body by producing an anti-clotting protein. In addition, it also finds application in anti-clotting surface inside several medical devices like renal dialysis machines, and test tubes among others.
 

Based on product terrain, U.S. heparin market is spit into unfractionated heparin and low molecular weight heparin, among which, the latter segment accounted for a revenue share worth USD 87.7 million in the recent past. Unfractionated heparin (UFH) is a quick-action blood thinner that works with antithrombin, a natural protein in the body for blocking clot formations. It also wears off once the infusion is stopped. These characteristics along with the lower cost in comparison to other heparin formulations are fostering the segment growth.
 

Speaking of the application spectrum, venous thromboembolism segment secured 52.6% of U.S. heparin industry share in 2019 and is likely to gain considerable traction over the forecast timeline. The growth is attributable to substitution of low-molecular-weight heparin with UFH as it is a better anticoagulant for initial treatment of individuals suffering from venous thromboembolism.
 

Elaborating on the distribution channel, the industry is fragmented into online pharmacy, hospital pharmacy, and retail pharmacy. Among these, hospital pharmacy segment is slated to record 6.8% CAGR through 2026.
 

Leading players influencing U.S. heparin market trends are Yantai Dongcheng Biochemical Co., Ltd., Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Sanofi S.A., Pfizer, Inc., Nanjing King-friend Biochemical Pharmaceutical Co., Ltd., Leo Pharma A/S, Fresenius Kabi AG, Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd., and Amphastar Pharmaceuticals, Inc.

Chat with us